EGFR/CDK2-IN-3

EGFR/CDK2-IN-3 (compound 4b) is a dual inhibitor of EGFR and CDK-2 with IC50s of 71.7 and 113.7 nM, respectively. EGFR/CDK2-IN-3 induces apoptosis in MCF-7 cells and arrests the cell cycle in the S phase. EGFR/CDK2-IN-3 has significant anti-cancer cell toxicity and inhibits MCF-7 with an IC50 of 3.16 μM[1].

Product Specifications

UNSPSC

12352005

Target

CDK; EGFR

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/egfr-cdk2-in-3.html

Solubility

10 mM in DMSO

Smiles

O=C(C1=CN(C2=CC=CC=C2)N=C1C3=NN4C(SC3)=NN=C4C5=CC=CC=C5)C6=CC=C7C=CC=CC7=C6

Molecular Formula

C30H20N6OS

Molecular Weight

512.58

References & Citations

[1]Salem M E, et al. Synthesis and Anti-Breast Cancer Potency of Mono-and Bis- (pyrazolyl [1, 2, 4] triazolo [3, 4-b][1, 3, 4] thiadiazine) Derivatives as EGFR/CDK-2 Target Inhibitors[J]. ACS Omega, 2023.. . .